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Background: Clopidogrel hypersensitivity(HS)manifesting is a recognized compli-
cation affecting w3% of treated patients. Contrary to other drug allergy, the immu-
nologic basis of clopidogrel HS are poorly understood. In this report, we characterize
the cellular and immunologic mechanism of clopidogrel HS and describe a novel
Lymphocyte Toxicity Assay (LTA) for the conﬁrmation of diagnosis in affected
individuals.
Methods: Blood and skin samples from 32 patients with a conﬁrmed diagnosis of
clopidogrel HS were analyzed for hematologic and an immunologic response during
the active phase of clopidogrel HS. LTA and TNF alpha assay were performed after a
minimum of 12 months post clopidogrel discontinuation.
Results: The hematological screen identiﬁed a signiﬁcant increase in circulatory
neutrophil and decrease in lymphocyte with no change in the eosinophil counts. The
immunohistochemistry of the affected areas showed a predominance of CD4+, CD1+
with few CD8+, CD 68+ cells and absence of caspase staining. The LTA and TNF
alpha values were increased for clopidogrel HS compared to control patients, ﬁgure 1
and 2. ROC curves demonstrated excellent accuracy for the diagnosis of Clopidogrel
HS (ﬁgure 3) with sensitivity of 86% and speciﬁcity of 100% for LTA >16%.Conclusions: Clopidogrel HS is mediated by cellular immunity in contrast to the
humoral response seen for most other drug reactions. LTA is a novel test that offers
high sensitivity and speciﬁcity for accurate diagnosis in susceptible individuals.
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Background: The optimal duration of dual antiplatelet therapy (DAPT) after drug-
eluting stents (DES) implantation has not been determined. Current ACCF/AHA
guidelines recommend 12-month DAPT based on observational evidence suggesting
an increased risk of stent thrombosis after premature DAPT cessation. We performed a
meta-analysis of randomized clinical trials comparing short-term (3-6 months) DAPT
with guideline-recommended DAPT (at least 12 months) in patients undergoing
percutaneous coronary interventions (PCI) with DES implantation.
Methods: PubMed, EMBASE and CENTRAL were searched for published ran-
domized trials directly comparing short-term versus ACCF/AHA guideline-recom-
mended (at least 12 months) DAPT after PCI with DES up to March 2013. Risk ratios
(RR) were used as a the metric of choice for treatment effects by using random- and
ﬁxed-effects models. I-squared index was applied to assess heterogeneity across trials.
The primary safety and efﬁcacy outcomes were any bleeding and the composite of
cardiac death and myocardial infarction, respectively. The secondary efﬁcacy outcome
was deﬁnite or probable stent thrombosis. Outcomes were analyzed at maximum
available follow-up.
Results: Four trials were identiﬁed: EXCELLENT (6-month vs. 12-month DAPT,
N¼1,443), PRODIGY (6-month vs. 24-month, N¼1970), RESET (3-month vs.
12-month DAPT, N¼2,117), and OPTIMIZE (3-month vs. 12-month DAPT,
N¼3,119) – including a total of 8,649 patients with at least 12-month follow-up. Short-
term DAPT was associated with a reduced risk of any bleeding as compared to guide-
line-recommended DAPT (RR 0.64, 95% CI 0.46-0.89). With respect to antithrombotic
efﬁcacy, risks of cardiac death or myocardial infarction (RR 1.08, 95% CI 0.82-1.32)
and deﬁnite/probable stent thrombosis (RR 1.24, 95% CI 0.76-2.02) did not differ
between short-term DAPT compared with guideline-recommended DAPT. There was
no statistically signiﬁcant heterogeneity across trials for any of the analyzed outcomes.
Conclusions: Short-term DAPT is associated with a reduced risk of bleeding but
preserves antithrombotic efﬁcacy compared with ACCF/AHA guideline-recom-
mended 12-month DAPT after PCI with DES implantation.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhaTCT-486
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Background: Chronic kidney disease (CKD) and diabetes mellitus (DM) affect
platelet function and cardiovascular risk. Despite substantial overlap, the impact of
CKD and DM, in combination vs. alone, on platelet reactivity and adverse events after
percutaneous coronary intervention (PCI) remains unclear.
Methods: ADAPT-DES is a prospective registry of 8,582 patients undergoing PCI
with drug-eluting stents (DES). All patients underwent VerifyNow platelet function
testing. We deﬁned high platelet reactivity (HPR) after clopidogrel loading as platelet
reactivity units (PRU) >208, and CKD as a creatinine clearance < 60 ml/min. We
examined frequency of HPR and 2-year MACE rates in patients with CKD alone
(n¼881), DM alone (n¼2258), both CKD and DM (n¼521) and neither CKD nor DM
(n¼4883).
Results: HPR in patients with CKD alone, DM alone, both CKD and DM and neither
CKD nor DM was 44.9%, 54.4%, 55.9% and 35.6%, respectively (p< 0.001). The
2-year composite rates of cardiac death, MI or stent thrombosis were highest in
patients with both conditions, similar in those with CKD or DM alone, and lowest in
the absence of either CKD or DM (Figure). After adjusting for risk factors (including
HPR), hazard ratios (95% CI) for MACE were 1.56 (1.16-2.10), 1.50 (1.22-1.86) and
2.43 (1.80-3.29) in patients with CKD alone, DM alone, and both CKD and DM,
compared to those without CKD or DM, respectively.
Conclusions: CKD and DM both predict HPR on clopidogrel, with additive risk. The
negative prognostic impact of CKD and DM on 2-year MACE rates was greatest in
patients with both conditions, independent of on-treatment platelet reactivity.rmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors B143
